|
We asked 50 pharma leaders, has your department been downsized? If so, by how much?
| Up to 10% |
43% |
10-25% |
27% |
| 25-50% |
7% |
| More than 50% |
23% |
 |
|
|
|
|
|
|
|
21 May, 2013
|
|
India and IPR: A Post-Glivec Special
In this month’s issue of Pharm Exec Global Digest — Patents Focus: Is Indian Pharma Growth Doomed?; The Cost of Weakening IPR; Excitement for EU’s Unitary Patent; and the UK Patent Box ...Read more |
UK: A New Era for NICE
NICE has not only survived the healthcare reforms sweeping the UK’s health service, but has emerged in a stronger and arguably more controversial position, writes Leela Barham ... Read more |
Data: Is Bigger Always Better?
One of things that we’re hearing a lot about right now is big data. We’re told that we’re entering an era of big data that will come to transform business and government services alike. For data, so the thinking goes, the bigger the better. But, asks Agnitio’s Morten Hjelmsoe, is this always the case? ... Read more
|
Smarter Multichannel Marketing
Jan van den Burg calls for better orchestration of multichannel communications across sales and marketing ... Read more
|
|
|
|
